DUBLIN, October 27, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Hemophilia Drugs Market 2016-2020" report to their offering.
The report forecasts the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.
One trend gaining traction in this market is increase in technological innovations. Currently, most of the hemophilia therapeutics available in the market are short-acting i.e., used only for when the individual suffers from bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products.
According to the report, drugs with prolonged action will drive the market. Earlier, parenteral formulations for treating hemophilia B required frequent administration of replacement factors. Drugs with favorable pharmacokinetic profiles, including prolonged mechanism of action are fast gaining acceptance among physicians and individuals. These long-acting formulations reduce the need for repeated dosing of medications, reducing injection site pain. ALPROLIX by Biogen is one such drug.
Further, the report states that the diagnosis rates of hemophilia are very low, especially in the developing countries like China and India. In the developed regions such as Germany, Australia, and the US, the disease diagnosis rate is more than 80%. However, in developing countries such as China, India, and Indonesia, disease diagnosis rates are 56%, 12%, and 4%, respectively. The low diagnosis rate of hemophilia in developing countries is due to inadequate treatment facilities, limited disease knowledge, and a shortage of treatment supplies.
- CSL Behring
- Novo Nordisk
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by type of disease
PART 08: Market segmentation by type of therapy
PART 09: Market segmentation by type of disease management
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Key vendor analysis
PART 18: Appendix
For more information on this topic, check out the Pharmaceuticals and Healthcare section of the Research and Markets' blog.
For more information about this report visit http://www.researchandmarkets.com/research/8vm8tg/global_hemophilia
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-hemophilia-drugs-market---analysis-technologies--forecasts-to-2020---focus-on-prophylactic-treatment-is-driving-growth----research-and-markets-300352624.html
SOURCE Research and Markets